Poolbeg Pharma faster and more cost effective than traditional biotech models

Poolbeg Pharma faster and more cost effective than traditional biotech models
[shareaholic app="share_buttons" id_name="post_below_content"]

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light, clinical model which enables them to develop multiple products faster and more cost effectively than the traditional biotech model.

This week the company successfully joined the London Stock Markets AIM and joining me to discuss the IPO is Poolbeg Pharma Chairman Cathal Friel and CEO Jeremy Skillington.

Cathal tells us a little more about the company, explains why he made a significant investment into Poolbeg. Jeremy explains how the company model is different to other Pharma companies, first day dealings and plans for the months ahead.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
Poolbeg Pharma secures US patent approval for POLB 001, enhancing its IP portfolio and advancing treatments for severe influenza and cytokine storms.
Poolbeg Pharma to showcase POLB 001's promising results in reducing CRS at ASH 2024, highlighting breakthroughs in cancer immunotherapy safety.
Discover six high-growth AIM-listed British companies delivering exceptional returns, with share prices surging up to 150% in the past year.
Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF) has updated its registered address to 40 Bank Street, Floor 24, London, E14 5NR, United Kingdom.

Search

Search